Status:

COMPLETED

Study of Resection Combined With Stereotactic Radiosurgery for 1 to 3 Brain Metastases

Lead Sponsor:

University of Rochester

Conditions:

Neoplasm Metastasis

Eligibility:

All Genders

18+ years

Brief Summary

This study is to look more closely at the tumor removed during your surgery, and to follow your condition after your treatment. The purpose of this study is to determine what side effects are common ...

Eligibility Criteria

Inclusion

  • Patients must have a previously histopathologically proven diagnosis of malignancy.
  • Patients must be evaluated by Neurosurgery and Radiation Oncology
  • Patients must have 1-3 brain metastases seen on MRI or CT imaging. At least one brain metastases must be considered resectable by craniotomy as determined by the treating neurosurgeon. Brain lesion resection must be considered standard of care. A not uncommon situation is for a patient to undergo resection of a solitary metastasis, but prove to have more lesions on subsequent MRIs (perhaps too small to be seen on a pre-operative MRI). These patients will be eligible if the total number of lesions is 1-3.
  • All lesions must be treatable by SRS as determined by the treating neurosurgeon and radiation oncologist.
  • All lesions must be \<4 cm in greatest dimension. For patients with more than 1 brain metastases, only 1 lesion can exceed 3 cm in greatest dimension.
  • In patients treated to the post-op surgical cavity, this cavity must be encompassed by a CTV of \<5 cm.
  • Patients must have a Karnofsky performance status ≥60.
  • Extracranial disease must not be considered imminently life threatening (\<2 month anticipated survival from extracranial disease).
  • Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.

Exclusion

  • KPS\<60
  • life expectancy \> 2 months

Key Trial Info

Start Date :

January 14 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 28 2022

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT00904553

Start Date

January 14 2009

End Date

March 28 2022

Last Update

May 9 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Radiation Oncology, University of Rochester Medical Center

Rochester, New York, United States, 14642